Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers.
The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.
It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs.
The company was incorporated in 2011 and is headquartered in Suzhou, China.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 29, 23 | -0.42 Decreased by -16.67% | -0.38 Decreased by -10.53% |
| Aug 31, 23 | -1.48 Decreased by -92.21% | -0.38 Decreased by -289.47% |
| May 31, 23 | -0.38 Increased by +28.30% | -0.38 |
| Mar 28, 23 | -1.55 Decreased by -229.79% | -0.40 Decreased by -287.50% |
| Nov 30, 22 | -0.36 Decreased by -33.33% | -0.36 |
| Aug 30, 22 | -0.77 Decreased by -28.33% | -0.65 Decreased by -18.46% |
| Jun 1, 22 | -0.53 Increased by +13.11% | -0.53 |
| Mar 31, 22 | -0.47 Increased by +69.68% | -0.67 Increased by +29.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | N/A Decreased by -100.00% | -8.51 M Decreased by -107.02% | - - |
| Mar 31, 24 | N/A Decreased by -100.00% | -8.51 M Increased by +74.63% | - - |
| Dec 31, 23 | 407.87 K Increased by +N/A% | -7.42 M Decreased by N/A% | Decreased by -1.82 K% - |
| Sep 30, 23 | 407.87 K Decreased by -84.81% | -7.42 M Increased by +54.10% | Decreased by -1.82 K% Decreased by -202.10% |
| Jun 30, 23 | 17.30 M Increased by +340.86% | -4.11 M Increased by +91.38% | Decreased by -23.76% Increased by +98.04% |
| Mar 31, 23 | 5.57 M Decreased by -40.15% | -33.52 M Increased by +21.40% | Decreased by -602.08% Decreased by -31.34% |
| Dec 31, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Sep 30, 22 | 2.68 M Increased by +N/A% | -16.16 M Decreased by N/A% | Decreased by -602.08% - |